Stockscreener 앱 받기
7.58
6.61%
0.47
시장 영업 전:
7.70
0.12
+1.58%
전일 마감가:
$7.11
열려 있는:
$7.14
하루 거래량:
67,193
Relative Volume:
1.14
시가총액:
$26.26M
수익:
-
순이익/손실:
$-31.11M
주가수익비율:
-4.9542
EPS:
-1.53
순현금흐름:
$-28.18M
1주 성능:
+1.61%
1개월 성능:
-29.05%
6개월 성능:
-44.47%
1년 성능:
-82.00%
1일 변동 폭
$7.14
$7.80
1주일 범위
$7.00
$7.80
52주 변동 폭
$5.3495
$49.27
Tempest Therapeutics Inc Stock (TPST) Company Profile
명칭
Tempest Therapeutics Inc
전화
415-798-8589
주소
2000 SIERRA POINT PARKWAY, BRISBANE
TPST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
7.58 | 26.26M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-08 | 개시 | Jefferies | Buy |
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - GlobeNewswire
FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN
Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive
Tempest to explore alternatives to advance promising pipeline - The Pharma Letter
HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com
Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News
Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa
Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks
Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com
Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com
Tempest Therapeutics evaluates strategic options amid advancements - Investing.com
Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire
Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia
Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada
Tempest Therapeutics Announced 1-For-13 Reverse Stock Split - MarketScreener
TPST stock touches 52-week low at $0.69 amid market challenges - Investing.com Canada
TPST stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update - Defense World
Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World
FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World
HC Wainwright Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World
Scotiabank Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World
Scotiabank Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $7.00 - Armenian Reporter
Tempest Therapeutics (NASDAQ:TPST) Given New $16.00 Price Target at HC Wainwright - The AM Reporter
Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges - TipRanks
H.C. Wainwright cuts Tempest Therapeutics stock target to $16 By Investing.com - Investing.com UK
Tempest Therapeutics Inc. (TPST) reports earnings - Quartz
Why Super Micro Computer Stock Was Sliding This Week - The Globe and Mail
Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire
Tempest's Cancer Drug Shows 6-Month Survival Gain, Lands Major Roche Partnership - Stock Titan
Tempest Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Tempest Announces Amezalpat Poster Presentation at the 2025 - GlobeNewswire
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Yahoo
Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 - Stock Titan
Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace
Tempest Therapeutics advances Phase 2 trial for cancer prevention By Investing.com - Investing.com Australia
FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire
Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice - Marketscreener.com
Tempest Therapeutics Inc (TPST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.00%
자본화:
|
볼륨(24시간):